Hipertensiunea pulmonară

Objectives

Provide a national clinical protocol for pulmonary hypertension that standardises classification, diagnosis, risk assessment, treatment, referral and follow-up across primary, secondary and tertiary services, including a specialist reference-centre model.[1][2][3]The protocol covers pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension associated with cardiac disease, lung disease or hypoxaemia, congenital heart disease, portal hypertension, human immunodeficiency virus infection, connective-tissue disease and paediatric conditions.[4][5][6][7]

• Promote early detection through screening of people at increased risk, including first-line relatives of patients with confirmed idiopathic or hereditary pulmonary arterial hypertension, and through assessment of persistent exertional breathlessness after pulmonary embolism.[8][9][10]
• Confirm and classify disease using echocardiography, right-heart catheterisation, haemodynamic assessment and targeted investigations to establish the underlying clinical group.[11][12][13]
• Reduce mortality, morbidity, hospitalisation and disease complications through timely intervention, supportive care, disease-specific treatment and management of underlying causes.[14][15][16]
• Achieve or maintain low-risk status in pulmonary arterial hypertension, recognising intermediate risk as an inadequate response for most patients and escalating treatment when needed.[17][18]
• Increase the proportion of confirmed patients receiving permanent specific treatment, modify ineffective treatment, improve primary-care patient education and reduce exacerbation or progression among supervised patients.[10][19]
• Support informed patients and families through documented discussions and patient guidance on diagnosis, disease progression, complications, treatment adherence and prompt reporting of deterioration.[19][20]

Implementation

Implement care through a tiered pathway in which primary care identifies risk and provides continuing supervision, secondary services complete diagnostic assessment, and tertiary specialist centres confirm complex diagnoses, select treatment and manage advanced disease.[14][15][21]Patients with suspected pulmonary arterial hypertension, severe pulmonary hypertension, right-ventricular dysfunction or complex causes should be referred to specialised centres.[14][22][16]

• Apply a four-step diagnostic strategy: suspect and screen for pulmonary hypertension, detect it, identify its clinical class, and assess exercise capacity, right-heart haemodynamics and vasoreactivity.[12]Use echocardiographic probability, symptoms, associated conditions and risk factors to determine further investigations and the need for right-heart catheterisation.[23][24]
• Undertake targeted assessment using clinical examination, electrocardiography, chest radiography, Doppler echocardiography, pulmonary-function and blood-gas testing, ventilation-perfusion imaging, computed tomography, cardiac magnetic resonance imaging, laboratory and immunological tests, abdominal ultrasonography and catheterisation where indicated.[25][26][27]
• Investigate and treat left-heart, lung and other underlying disease before attributing pulmonary hypertension to a specific cause, while avoiding pulmonary arterial hypertension-specific medicines for pulmonary hypertension due to left-heart or lung disease.[22][16][28]
• Provide general and supportive measures, including vaccination, psychosocial support, supervised exercise where appropriate, diuretics for fluid retention and right-ventricular failure, oxygen for hypoxaemia, correction of anaemia and selectively indicated anticoagulation.[29][30]Avoid pregnancy in women with pulmonary arterial hypertension.[14][29]
• Use vasoreactivity testing only in experienced centres for idiopathic, heritable or drug-induced pulmonary arterial hypertension, to identify patients who may benefit from high-dose calcium-channel blockers.[13][31]Start disease-specific monotherapy, oral combination therapy, intravenous prostacyclin therapy or escalated multi-drug treatment according to risk, functional class and clinical response.[32][33][34]
• Manage chronic thromboembolic pulmonary hypertension through permanent oral anticoagulation, multidisciplinary treatment planning, pulmonary endarterectomy for eligible patients, riociguat for inoperable or persistent disease, and balloon pulmonary angioplasty where surgery is unsuitable.[9]
• Establish multidisciplinary reference centres with cardiology, respiratory medicine, nursing, imaging, catheterisation, psychological and social-support capacity; maintain links with genetics, connective-tissue disease, family-planning, endarterectomy, transplantation and congenital-heart-disease services.[35][36]These centres should provide clinical audit, professional and patient education, research collaboration, rapid transfer arrangements and communication with patient associations.[37][38][36]
• Monitor clinical status through World Health Organization functional class, exercise capacity, biomarkers, echocardiography and haemodynamics, with stable pulmonary arterial hypertension patients reviewed every three to six months.[39][40][41]Track implementation through indicators for screening eligible relatives, permanent treatment coverage, documented treatment modification, patient education and disease exacerbation or progression.[10][19]
• Provide primary-care institutions with family-doctor staff, basic examination equipment, electrocardiography, pulse oximetry, laboratory testing, oxygen and specified medicines; equip higher-level services with specialist staff, advanced diagnostics and access to pulmonary hypertension therapies.[42][43][44]The protocol identifies resource requirements but does not specify monetary budgets, financing sources, allocations or funding gaps.[41][42]

Monitoring & Evaluation

The protocol combines implementation monitoring with clinical surveillance for pulmonary hypertension, particularly pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. It uses structured diagnostic assessment, risk stratification, periodic follow-up, service-volume thresholds and clinical audit, but does not set out a unified national reporting system, numerical targets, surveillance database or named accountability body.[45][36][41]

• Monitor implementation through a dedicated set of protocol indicators, supported by an annex and patient guide; the extract does not reproduce the full indicator set or reporting arrangements.[45]
• Screen first-degree relatives of patients with confirmed idiopathic pulmonary arterial hypertension in primary care and calculate the proportion screened during the relevant six-month period from the number screened and the eligible supervised population.[10]
• Measure the proportion of confirmed idiopathic pulmonary arterial hypertension patients receiving permanent specific treatment during each relevant six-month period.[10]
• Record treatment modification, including dose escalation or addition of a medicine class, when previous treatment has not achieved therapeutic goals.[10]
• Measure the proportion of supervised patients receiving documented education during the preceding three months and the proportion experiencing exacerbation, incident disease or disease progression during the preceding year.[19]
• Assess severity and therapeutic response through clinical findings, World Health Organization functional class, signs of right-heart failure, symptom progression or syncope, exercise capacity, biochemical markers, echocardiography and haemodynamic measures.[46][17]
• Classify patients as low, intermediate or high risk of clinical deterioration or death, with achievement or maintenance of low risk as the treatment objective; intermediate risk is generally considered an inadequate response.[17]
• Review stable patients every three to six months and use the resulting assessment to categorise status as stable and satisfactory, stable but unsatisfactory, or unstable with deterioration.[17][18]
• Repeat clinical functional assessment, electrocardiography, six-minute walk testing and laboratory tests every three to six months; repeat cardiopulmonary exercise testing, echocardiography, extended laboratory tests and blood-gas analysis every six to twelve months where indicated.[40]
• Undertake reassessment three to six months after a treatment-regimen change and whenever clinical deterioration occurs.[40]
• Use right-heart catheterisation to confirm relevant diagnoses, quantify haemodynamic dysfunction and assess treatment efficacy in selected patients; conduct acute vasoreactivity testing in experienced centres for idiopathic, hereditary or drug-induced pulmonary arterial hypertension.[13][47][31]
• Define a positive acute vasoreactivity response as a reduction in mean pulmonary artery pressure of at least 10 mmHg to 40 mmHg or less, while cardiac output is maintained or increased.[13][31]
• Use the six-minute walk test, cardiopulmonary exercise testing, right-ventricular assessment, right-atrial pressure, cardiac index, mixed venous oxygen saturation, and natriuretic peptides as clinical and prognostic monitoring domains.[47][39]
• Monitor liver function monthly for patients receiving ambrisentan or bosentan.[48]
• Require complete reassessment, including right-heart catheterisation, after three to four months of high-dose calcium-channel-blocker treatment.[49]
• Maintain clinical audit, survival analysis, continuing education and research as functions of pulmonary-hypertension reference centres; compare outcomes where multiple centres operate.[38][36]
• Use reference-centre activity thresholds as service indicators, including management of at least 50 pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension patients, assessment of at least two newly documented cases monthly, and at least 20 pulmonary arterial hypertension vasoreactivity tests annually.[36]
• Monitor more than 200 adult patients annually where feasible, with at least half diagnosed with pulmonary arterial hypertension; paediatric-centre thresholds of 30 to 50 patients annually may be adapted to national circumstances.[38]
• Avoid routine screening of asymptomatic pulmonary embolism survivors for chronic thromboembolic pulmonary hypertension.[9]
• Recognise evidence limitations: comparative epidemiological data across pulmonary-hypertension groups are unavailable, and a methodological approach and database are identified as needed to address demographic and clinical-course data gaps.[50]

Costing & Financing

No explicit monetary costs, budgets, funding allocations, financing sources, resource-mobilisation arrangements, funding gaps or economic assumptions are provided. The protocol instead identifies substantial workforce, diagnostic, equipment, medicine and specialist-centre requirements, without assigning financial values to them.[42][43][44]

• Provide primary-care capacity including a family doctor and assistant, basic examination equipment, electrocardiography, pulse oximetry, laboratory testing, oxygen, oral anticoagulants and calcium-channel blockers.[42]
• Provide consultative and hospital-level specialist staff, imaging, laboratory, endoscopy, angiography and advanced diagnostic capacity, alongside disease-specific and supportive medicines.[42][43][44]
• Develop multidisciplinary reference centres with inpatient, intensive-care, outpatient and emergency facilities; diagnostic services; specialist nursing; psychological and social support; and formal links to transplantation, pulmonary endarterectomy, genetics, connective-tissue disease and family-planning services.[35][36]
• Ensure access to nationally approved medicines for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.[35]
• Consider medicine cost among factors informing treatment selection, alongside treatment status, route of administration, interactions, comorbidities and clinician experience; no prices or affordability analysis are specified.[34]
• Recognise that higher-volume specialised centres are described as potentially clinically and economically more efficient, although no costing methodology or quantified efficiency estimate is supplied.[38]
• Note that the six-minute walk test is characterised as cost-free, but no wider costing is provided for catheterisation, imaging, exercise testing, vasoreactivity testing, medicines or transplantation.[47]